<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="104219">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01930461</url>
  </required_header>
  <id_info>
    <org_study_id>VO72.12</org_study_id>
    <nct_id>NCT01930461</nct_id>
  </id_info>
  <brief_title>Dose Ranging Study of SLIT Tablets of House Dust Mite Allergen Extracts (HDM) in Adults With HDM-associated Allergic Asthma</brief_title>
  <official_title>A Dose Ranging Study Investigating the Efficacy and Safety of Sublingual Immunotherapy Tablets of House Dust Mite Allergen Extracts in Adults With House Dust Mite-associated Allergic Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stallergenes</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stallergenes</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <authority>Germany: Paul-Ehrlich-Institut</authority>
    <authority>Czech Republic: State Institute for Drug Control</authority>
    <authority>Slovakia: State Institute for Drug Control</authority>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
    <authority>Spain: Agencia Española de Medicamentos y Productos Sanitarios</authority>
    <authority>Denmark: Danish Health and Medicines Authority</authority>
    <authority>Belgium: Federal Agency for Medicines and Health Products, FAMHP</authority>
    <authority>Bulgaria: Bulgarian Drug Agency</authority>
    <authority>Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products</authority>
    <authority>Austria: Austrian Medicines and Medical Devices Agency</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the efficacy and safety of different doses of
      sublingual tablets of house dust mite allergen extracts as compared to placebo in adults
      with house dust mite-associated allergic asthma.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Anticipated">September 2015</completion_date>
  <primary_completion_date type="Anticipated">July 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Effect on the Asthma control test (ACT) score</measure>
    <time_frame>13 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Assessment of the effect of one year of treatment of 3 different doses of sublingual immunotherapy tablets of house dust mite (HDM) allergen extracts as compared to placebo on the Asthma Control Test™ (ACT) score, in adults with HDM-associated allergic asthma</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect on the Rhinoconjunctivitis symptoms and rescue medication use</measure>
    <time_frame>Measured during the last 3 months of the trial</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline on the Quality of Life using the AQLQ</measure>
    <time_frame>Measured during the last 6 months of the trial</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of asthma exacerbations</measure>
    <time_frame>Measured during the last 6 months of the trial</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and percentage of subjects with treatment-emergent AEs</measure>
    <time_frame>Measured during 13 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Changes of Immunological parameters (HDM-specific IgE and IgG4 values)</measure>
    <time_frame>13 months</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">480</enrollment>
  <condition>Asthma</condition>
  <condition>House Dust Mite Allergy</condition>
  <arm_group>
    <arm_group_label>SLIT of House Dust Mite (HDM) allergen extracts (A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sublingual Immunotherapy Tablets (SLIT) of HDM allergen extracts, 3 different doses (A)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tablets Matching the SLIT HDM allergen extracts</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SLIT of HDM allergen extracts</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sublingual Immunotherapy Tablets (SLIT) of HDM allergen extracts, 3 different doses (B)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SLIT of HDM allergen extracts (C)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sublingual Immunotherapy Tablets (SLIT) of HDM allergen extracts, 3 different doses (C)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Biological/Vaccine: SLIT tablets of HDM allergen extracts (A)</intervention_name>
    <arm_group_label>SLIT of House Dust Mite (HDM) allergen extracts (A)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Biological/Vaccine: Matching placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Biological/Vaccine: SLIT tablets of HDM allergen extracts (B)</intervention_name>
    <arm_group_label>SLIT of HDM allergen extracts</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Biological/Vaccine: SLIT tablets of HDM allergen extracts (C)</intervention_name>
    <arm_group_label>SLIT of HDM allergen extracts (C)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent.

          -  Male or female from 18 to 50 years of age.

          -  Diagnosed asthma and rhinitis with medical history consistent with HDM-induced
             allergic asthma and rhinitis.

          -  Positive SPT to HDM and and HDM-specific IgE serum value ≥ 0.7 kU/L.

          -  Stable asthma therapies.

          -  Spirometry (pre-bronchodilator) with best FEV1 ≥ 70% of the predicted value.

          -  Spirometry with reversibility in FEV1 of ≥ 12% and ≥ 200 mL.

          -  Asthma Control Test™ (ACT) score ≤ 19.

        Exclusion Criteria:

          -  Former smoker with &gt; 10 pack year history or current smoker.

          -  Patient with a urine level of cotinine ≥ 500 ng/mL.

          -  Co-sensitisation to any allergen possibly leading to clinically relevant symptoms
             likely to significantly change the asthma symptoms of the subject during the study.

          -  Patient who received allergen immunotherapy for HDM within the past 10 years.

          -  Ongoing immunotherapy for an aeroallergen other than house dust mite.

          -  Patient with any oral condition that could confound the safety assessments or
             planning to have a dental extraction during the study.

          -  Patient treated with beta-blockers, tricyclic antidepressants or monoamine oxidase
             inhibitors (MAOIs).

          -  Pregnant women or breast-feeding/lactating.

          -  Women with childbearing potential who are not using a medically accepted birth
             control method.

          -  Patient with a past or current disease, which as judged by the Investigator, may
             affect the patient's participation in, or the outcome of this study.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pascal Demoly, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Montpellier, France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU Arnaud de Villeneuve</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NHC, Hôpitaux Universitaires de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Berlin - Allergie-Centrum-Charité</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPZOZ Uniwersytecki Szpital Kliniczny Nr 1im.N.Barlickiego w Uniwersystetu Medycznego w Łodzi</name>
      <address>
        <city>Lodz</city>
        <zip>90-153</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Majorek-Olechowska Bernadetta</name>
      <address>
        <city>Tarnow</city>
        <zip>33-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Poland</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 28, 2014</lastchanged_date>
  <firstreceived_date>August 16, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
